Five chromatographic and six immunoassay techniques were compared using data reported by 131 participants in the UK National External Quality Assessment Scheme for Drugs of Abuse in Urine. Twenty five samples were studied containing none or one of three concentrations of amphetamine, barbiturates, benzodiazepines, benzoylecgonine, methadone and morphine. Technique sensitivity and specificity achieved with realistic clinical samples of 25 mL vol were assessed as the percentage of true positive and true negative tests, respectively. Thin-layer chromatography was inadequate for the detection of several analytes, the sensitivity
for O·5 mg/L of benzoylecgonine being < 30070, and for 1. 5 mg/L of amphetamine < 861170. Gas chromatography with mass spectrometry was significantly less sensitive than other techniques for the detection of O·5 mg/L of benzoylecgonine (71%) and I· 5 mg/L of morphine (88%). High-performance liquid chromatography was the most sensitive for amphetamine. Immunoassays performed well when operating above their specified cut-off concentrations but, because they are directed to quinalbarbitone showed reduced cross-reactivity with amylobarbitone, the barbiturate more commonly prescribed in the UK.
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The techniques available for the detection of drugs of abuse in urine samples have been influenced by the development of large programmes for undertaking random screening in the military and employment sectors in the USA. The military programme established a two-stage testing procedure. An immunological based screening test was followed by a separate confirmatory test by a different technique for those samples positive in the preliminary screen. Gas chromatography with mass spectrometry (GC/MS) subsequently became the required technique for confirmation. The USA federal workplace testing programme operates similarly to guidelines defined by the National Institute for Drug Abuse (NIDA). NIDA specified the analyte groups to be investigated and the cut-off concentrations to be used in both the screening and confirmatory tests ( Table 1) . The substantial investment made in these programmes has determined that the commercial immunoassay kits supplied by the major American manufacturers are tailored for use with the panel of drugs and cut-off concentrations defined by NIDA.
Drug testing in the UK has developed differently from the American pattern. The main use of urine analysis has been in the follow-up of addicts under clinical care. Limited employment screening has been introduced for employees in 'high-risk' areas. Local laboratory services have developed to provide routine clinical monitoring. Sample throughput can be relatively low; the average workload of members of the United Kingdom National External Quality Assessment Scheme 
·Cocaine. "Opiates. SEM = Standard error of mean; UKNEQAS: UK National External Quality Assessment Scheme; NIDA: US National Institute for Drug Abuse; NS = not specified. Numbers of samples are given in Tables 3 and 4. (UKNEQAS) for Drugs of Abuse in Urine in 1990 was 221 samples each month. I Use of large automated analysers is therefore less frequent than in the USA and techniques such as thin-layer chromatography (TLC) are popular. Confirmation by GC/MS is generally available only in regional centres.
Evaluation of the outcome of testing for drugs of abuse can show high levels of accuracy when undertaken by selected laboratories able to perform confirmatory testing.s" Such proficiency tests do not, however, provide separate data on the performance of the individual techniques when applied in the routine laboratory environment. Since 1987, an external quality assessment or proficiency testing scheme has operated in the UK for clinical and other interested laboratories. Of over 150 participants, some 770/0 are fromthe UK and the remainder from other European countries and the Near East. Reports from this schemet-' and from its Spanish equivalent" have provided data on the quality of testing services. We report here a comparison of techniques for detection of drugs of abuse based on data reported by members of the UKNEQAS for drugs of abuse between March 1990 and August 1992. The data Ann Clin Biochem 1994: 31 collection techniques used avoided the problem of under-reporting of true negative results of our previous report" and data are included for the first time on the performance of GC/MS in European laboratories.
MATERIALS AND METHODS
Members of the UKNEQAS for drugs of abuse were supplied with freeze-dried aliquots of 25 mL of urine in sets of three at 4 "month intervals. Samples were presented in glass vials sealed with rubber bungs and crimped aluminium seals. Urine was heated at 60°C for 1·5 h prior to dispensing and lyophilization, and contained a maximum of 0-1% sodium azide as a preservative.
Real clinical material was simulated by basing samples, where practicable, on urine collected from clinical sources. Urine free from analytes of abuse was supplied by the authors, and urine was collected from patients being detoxified on a locked ward who were receiving treatment with methadone alone or with methadone and diazepam. Some of the latter samples of urine also contained residual metabolites from temazepam use. A number of samples contained additional metabolites from the administration of therapeutic agents and some patients' samples contained cannabinoid metabolites. A number of analytes were added as part of studies not presented here. The other analytes present were methylamphetamine (5), phenylephrine (1), phenylpropanolamine (1), brompheniramine (I), phenobarbitone (2), codeine (1), buprenorphine (I), cannabinoids (10), salicylates (5), amoxycillin (I), clavulanic acid (I), co-trimoxazole (3) and pemoline (1). The numbers in parentheses are the number of occurrences.
The data presented here concern six analytes present in combinations at zero and three concentrations in a total of 25 samples distributed by the Scheme. The three concentrations, termed low, medium and high, were designed to be one half, 1·5 times and 4·5 times the cut-off concentration used by the Scheme (Table 1) . The Scheme thresholds were chosen to meet the clinical criterion that the use of a bioeffective dose of a psychoactive substance in the previous 24 to 48 h should not be missed by the analysis after allowing time for patient admission and sample collection. The cut-off for the cocaine metabolite was increased relative to the clinically determined cut-off to permit confirmation by a second independent technique likely to be available in a typical district general hospital. Inclusion of samples containing drug concentrations both above and below these thresholds enabled assessment of the performance of the techniques in the clinically relevant concentration range. The target concentrations for the six analytes are given in Table 1 . The number of samples at each concentration are given in Tables 2 and 3 .
The required concentrations of free methadone or benzodiazepine metabolites were obtained by dilution of material from patients with blank urine. The dilution required was determined by the Syva (Palo Alto, CA, USA) Emit drugs of abuse in urine (d.a.u.P') technique by titrating the patients' urine to obtain a reading close to the low standard of 0·3 mg/L. On nine occasions benzodiazepines were present from use of patient urine. Four samples were spiked with oxazepam. Other analytes were added to the urine at weighed-in concentrations. The accuracy of the weighed-in drug concentrations and of those obtained by dilution of patient urine were verified from quantitative measurements by Abbott TDx™ (Abbott Laboratories Ltd, Diagnostics Division, Irving, TX, USA), radioimmunoassay (RIA), high-performance liquid chromatography (HPLC), GC and GC/MS reported by a number of Scheme participants (Mr Firth, Hurstwood Park Neurological Centre, Haywards Heath; Ms Morgan, Bronllys Hospital, Brecon; Ms Singer, GDRU Ltd., London; Dr Trafford, London Hospital Medical College, London; Dr Sommer, Linz, Austria; Dr Eberhard, Dortmund, Germany; Prof. Kaferstein, Cologne, Germany; Dr Lund, Oslo, Norway; Dr Beck, Stockholm, Sweden; Dr Bergqvist, Falun, Sweden and Dr Eriksson, Karlstad, Sweden). The weighed-in analytes were d,l-amphetamine, benzoylecgonine, morphine, amylobarbitone in eight samples and quinalbarbitone in one sample at 4· 5 mg/L. For the high concentrations of benzoylecgonine and benzodiazepines, data from pairs of samples containing two differing but similar drug concentrations have been combined. The data for an analyte were excluded where the concentration was inappropriate for the range under study or where an interferent was present. Thus data for amphetamine was excluded where methylamphetamine was present, for barbiturates where phenobarbitone was present, and for morphine where codeine was present.
For each sample, participants were asked to specify the result of all separate tests used to determine the presence or absence of the following six analytes or groups; amphetamine, barbiturates, benzodiazepines, cocaine or metabolites, methadone or metabolites, and morphine. Tests were identified using a classification of analytical techniques suggested by the Scheme. Test results were of the form 'positive', 'negative' or 'uncertain'. Where the same technique such as TLC was used twice under different conditions, participants were asked to make two test result entries on the forms supplied. In cases where participants reported separately the results of non-specific immunoassay tests for the amphetamines group or for opiates, the test data presented are a combination of the specific amphetamine or morphine results with the group test results.
In addition to the raw test results, participants were asked to present an overall clinical report having assessed the test results relative to the threshold concentrations specified by the Scheme. Reports were of the form 'present', 'not found' and 'test not available' . Reports of 'referred' were accepted from laboratories providing only a preliminary screening service where their screening test gave a positive result.
The results for each technique were totalled and estimates of technique sensitivity and specificity calculated as follows. Sensitivity was defined as: Comparisons between sensitivity of techniques were made by two-way analysis of variance between technique and drug concentration following an arc sine transformation of the percentage data. Significant differences between means were identified by the Student-Newman-Keuls test (P<0·05). Comparisons between techniques in specificity were made similarly following one-way analysis of variance.
The overall report data are presented in terms of the percentage of false positive or false negative results. Comparisons between the frequency of correct and false reports were made by chi-square tests.
The mean drug concentrations reported by Scheme participants are given in Table 1 . The amphetamine and benzodiazepine data are those by the Abbott TDx amphetamine/methamphetamine and benzodiazepine assays only. The apparent over-spiking of amphetamine resulted from the > 100070 cross-reactivity of d,l-amphetamine in the Abbott assay. If the data are corrected using the non-linear cross-reactivity values published by Abbott, the three mean measured concentrations become O' 5, 1· 7 and 3·0 mg/L respectively. The low measured values for benzodiazepines can be attributed similarly to the lower cross-reactivity of oxazepam and other benzodiazepine metabolites in the Abbott system compared with the Syva Emit method that was used in sample formulation. If the benzodiazepine measurements are assumed to be due entirely to the presence of oxazepam, the corrected means are 0'4, 0·9 and 4'2 mg/L, respectively. These approximate to mean values of O' 44, 1· 45 and 3·8 mg/L from an incomplete data set of chromatographic measurements. The barbiturate data in Table 1 include measurements by a variety of techniques. Those by Abbott TDx were corrected to compensate for the partial cross-reactivity of amylobarbitone. The technique classification and the mean number of measurements made by each technique per sample for the six test analytes are presented in Table 4 . TLC determinations are subdivided into those by the commercial Toxi-Lab systems (Mercia Diagnostics Ltd, Guildford, UK) which are termed TLC-kits and those by various in-house methods. Tests by the Syva Emit kits are grouped into those by Emit d.a.u.P' and jointly those by the Emit st™ and Emit Qst™ detection systems. Only data for specific morphine RIA are presented.
Variations in sensitivity of the different techniques at different drug concentrations are presented in Table 2 . Statistical comparison of the combined amphetamine and amphetamine group data showed that the two TLC techniques were significantly less sensitive than all other techniques and that the in-house TLC methods were significantly less sensitive than the TLC-kits group. The most sensitive technique overall was HPLC, especiallyat low drug concentrations where the other techniques ranged in sensitivity from 92070 for GC/MS to 82% for the Emit st/Qst group. All techniques lacked sensitivity at the low barbiturate concentration. The best technique at all concentrations of barbiturates was GC/MS which differed significantly from the four poorest techniques which were the two TLC groups and both Emit groups. Although some techniques, notably GC/MS, showed lower sensitivity at the low concentration of benzodiazepines, the only significant difference between techniques was shown by TLC-kits which differed from all other techniques and performed poorly throughout.
Benzoylecgonine presented the most difficult analytical challenge at the concentrations tested. The least sensitive techniques were the two TLC groups which differed significantly from all other techniques except GC and achieved only a 50% success rate at the high concentration. The next two techniques in ascending order of sensitivity were gas chromatography and GC/MS. The latter gave a 70% score at medium and high concentrations and was significantly less sensitive than several techniques. The low concentration of benzoylecgonine studied was below the threshold of several of the commercial immunoassay techniques. At concentrations above their threshold, the immunoassay kits performed well with sensitivity values > 96%. The best of the chromatographic techniques for benzoylecgonine was HPLC. It did not differ significantly in sensitivity from the immunoassay groups.
There was only one significant difference between techniques in measurements of methadone. The least sensitive technique overall was TLC in-house which differed significantly from all techniques except HPLC and GC. Several significant differences were detected in measurements of morphine. Least sensitive was the TLC-kit which differed from all other techniques. GC/MS and TLC in-house did not differ but were significantly less sensitive than the immunoassays. The remaining chromatographic techniques were numerically less sensitive Abbott TDx  17  15  19  23  7  20  Perkin Elmer  2  2  PFIA  RIA  3  2  4  BCL·  7   Total  laboratories  reporting  130  114  120  118  119  133 ·Opiates. See Table 2 for key to abbreviations. than the immunoassays but differed significantly only from the most sensitive RIA group. The percent specificity of techniques are displayed in Table 3 . No significant differences between techniques were detected in measurements of amphetamine(s), barbiturates, methadone and in the combined morphine-opiates data. For benzodiazepines and benzoylecgonine the TLCkits group, with specificity values of 83 and 92070, respectively, was significantly less specific than those techniques achieving > 96070. Differences from the more variable data for HPLC and RIA did not reach significance.
Consideration of the combination of tests used to determine the overall report showed that 21070 of 'not found' reports and 36070 of 'present' reports were confirmed by use of two or more tests. The percentage of false positive overall reports in samples from which test analytes were absent and the percentage of false negative reports in the medium and high samples containing analyte concentrations above the cut-off concentrations used by UKNEQAS are presented in Table 5 . The test combinations used when reporting errors occurred were compared with the test combinations for correct reports by chi-square tests. There was no reduction in the frequency of false positive reports when confirmatory tests were used(P>0·05). However, for amphetamine, barbiturates and morphine the use of confirmatory tests significantly reduced the frequency of false negative reports (P<0·05). A significant excess of false positive reports for barbiturates and benzodiazepines resulted from use of unconfirmed tests by TLC (P<0·05). A significantly higher frequency of unconfirmed TLC test results were also present in false negative reports for amphetamines, benzodiazepines, benzoylecgonine and morphine (P<0·05).
DISCUSSION
The data demonstrate significant differences in the sensitivity and specificity of techniques available for the detection of drugs of abuse in urine when applied to realistic clinical samples of 25 mL volume. The technique classification used, which implicitly includes sample extraction steps, was a combination of commercial immunoassay or TLC groups and of potentially more variable in-house TLC, GC and other chromatographic procedures. The findings with the in-house techniques relate to their average performance as currently implemented in Europe and the UK; it is possible that with greater commitment by a laboratory or in the 
·Opiates. FP = False positive; FN = false negative.
hands of more experienced analysts better performance than that observed may be achieved. A second limitation in the data is that a number of transcription and other non-assay-dependent errors will be present in the data. Such errors will not invalidate the significant between-technique differences found but will have reduced the sensitivity of the statistical comparisons.
The analysis demonstrates that TLC techniques as implemented are inadequate for the detection of several analytes at concentrations above the cutoff concentrations defined by the UKNEQAS as clinically significant. The commercial Toxi-Lab system had a sensitivity of 30070 for O' 5 mg/L of benzoylecgonine, 53070 for 1· 5 mg/L of benzodiazepines, 83070 for 1·5 mg/L of morphine and 86070 for 1· 5 mg/L of amphetamine. The corresponding percentages for in-house TLC techniques were 23,91,91 and 64070, respectively. The technique adopted as the benchmark in the drugs of abuse screening field, GC/MS, was significantly less sensitive than some other techniques for the detection of benzoylecgonine and morphine. The sensitivitywas an unsatisfactory 71070 for O' 5 mg/L of benzoylecgonine and was 88070 for 1· 5 mg/L of morphine. As expected, the analyte concentrations used presented few problems for the inherently more sensitive immunoassay techniques save where the lowest of the three drug concentrations approached or fell below the lower cut-offs of the kits, which have been tailored to NIDA guidelines. A point of note was the relatively poor sensitivity of the Emit and Abbott techniques for the detection of barbiturates. These kits are directed towards quinalbarbitone used in the USA and have lower cross-reactivities with amylobarbitone which tends to be involved in abuse cases in the UK.
Although we have presented data on the specificity of the various techniques, the formulation of the samples and data selection procedures have excluded problems arising from interference by compounds related to the test analytes. In addition to the data excluded because of the presence of known interferents, all data from analytically complex pooled addict samples circulated by the UKNEQAS during the study period were also excluded. The specificity data thus relates to analytically 'clean' specimens and are probably an underestimate of the difficulties likely to be encountered in the analysis of routine samples. Nevertheless, the data demonstrated significant non-specificity in Toxi-Lab detection of benzoylecgonine and benzodiazepines.
The limitations in the techniques quantified by the study are not unexpected. They are likely to be taken into account by analysts in their interpretation of the individual test results when determining whether additional confirmatory tests are required and finally in determining the overall report. Thus, the level of false reporting was better than the performance of individual techniques. The experience, analytical and interpretive capabilities of the analyst is thus of paramount importance. In our survey of Scheme participants in 1990,1 more than 50070 of staff had 2 years or less experience in drugs of abuse testing. There is a need for continued investment in staff training and for rigorous application of quality control procedures. Participation in educational programmes such as external quality assessment schemes should be apriority.
It was disappointing to note that there was no significant reduction in the number of false positive reports following use of confirmatory tests. However, with the exception of barbiturates which seem to present a specific problem, the number of false positive reports was low. The proportion of errors ranged from 0·8 to 1· 6%, and false positive reports for morphine did not differ significantly from zero.
False negative reports on samples containing clinically relevant drug concentrations were more Ann Clin Biochem 1994: 31 frequent. Amphetamine, benzodiazepines and morphine were missed at concentrations of 1·5 mg/L by some 7% to 8% of participants, the level of false reporting falling to 3% at high concentrations of 4·5 mg/L. The performance for barbiturates and benzoylecgonine was even less satisfactory with 13% and 16·5070 of errors, respectively, in the medium concentration samples. The difficulties in the analysis of samples containing benzoylecgonine are particularly disturbing in view of the scale of cocaine misuse. It is clear that acceptable screening services for this analyte cannot be based on TLC or the GC techniques as the primary technique. The significant reduction in the frequency of false negative reports for other analytes when confirmatory tests were performed is further evidence of the inadequate performance of some tests as primary screens.
